Biophysical Characterization of EVPs and other Macromolecular Nanoparticles

EVP 和其他大分子纳米颗粒的生物物理表征

• 批准号: 10702579
• 负责人: Jennifer Jones
• 金额: $ 68.61万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10702579
• 关键词: Area; Biological; Biology; Biomedical Research; Biophysics; Blood Tests; Blood Vessels; CCR; Cancer Patient; Clinical; Collaborations; Communities; Computer software; Detection; Disease; Foundations; Future; Goals; Immune; Immune Evasion; Immune response; Immunobiology; Investigation; Knowledge; Malignant Neoplasms; Measures; Medicine; Methods; Mission; Molecular; Monitor; Neoplasm Circulating Cells; Nucleic Acids; Patient Care; Protocols documentation; Radiation; Reproducibility; Research; Resolution; System; Tumor Biology; Vision; Work; anticancer research; base; biological systems; biophysical properties; exosome; extracellular vesicles; frontier; improved; interest; liquid biopsy; macromolecular assembly; microvesicles; multiple omics; nano; nanobiology; nanoparticle; nanoscale; neglect; neoplastic cell; novel; particle; programs; submicron; tool; treatment response; treatment strategy; tumor; tumor progression

Liquid biopsies are part of this emerging frontier in biomedical research. This frontier is of interest to all areas of biology and medicine and is of particular interest to the cancer research community. Circulating tumor cells (CTCs) and cell-free nucleic acids (cfNAs) are two types of liquid biopsies where clear progress has been made in the past decade towards understanding these CTC and cfNA tumor-related and systems-based biological information. Systematic, accurate, and reproducible studies of sub-micron extracellular vesicles (EVs) and other nanoscale macromolecular assemblies (collectively referred to hereafter as extracellular vesicles and particles, or EVPs) are difficult to perform due to a lack of robust and reliable tools for correctly measuring these submicron and nanoscale materials. CCR's mission is to improve the lives of all cancer patients by solving important, challenging, and neglected problems in cancer research and patient care. The Translational Nanobiology Section's particular expertise, perspective, collaborations, and vision within CCR is building bridges to span the existing gaps between basic biophysical and metrological first principles, advanced molecular multi-omics strategies, and clinical translational investigation in order to develop systematic, robust, and accurate ways to study EVPs tumor-, immune-, and stromal-/vascular- EVP compositions as they relate to tumor progression and treatment response in our cancer patients. Although the specific focus of my lab pertains most immediately to cancer and cancer-related immunobiology, we intend for our work to be a general asset to the biomedical research community. As such, my Section is committed to sharing our tools for general research use, so that they can accelerate studies in other diseases as well. The ultimate goal of my program is to leverage the information content in EVPs to interrogate biological systems in a systematic manner, that is, by identification and characterization of specific sub-sets of EVPs to 'read' the status of compartments represented by those sub-sets. The purpose of Projects 1 and 2 in the Translational Nanobiology Lab is to develop and demonstrate the use of new tools for the field to use that will enable us to monitor tumor, immune, and vascular/stromal systems in a manner that we hope will enable us to perform blood tests to detect relevant changes in those systems early in the course of radiation or other therapies, and we hope that this will more broadly serve as a foundation for enabling selectively (system-specific) adaptive treatment strategies in the future. Project 1 is focused on spanning the gap in available tools and knowledge to accurately characterize the liquid biopsy components, EVPs and their cargo, for Project 2.

液体活检是生物医学研究中新兴领域的一部分。该领域对所有生物学和医学领域都感兴趣，并且对癌症研究界特别感兴趣。循环肿瘤细胞（CTC）和无细胞的核酸（CFNA）是两种类型的液体活检，在过去的十年中，在了解这些CTC和CFNA肿瘤相关和基于系统的生物学信息方面已经取得了明显的进展。亚微米细胞外囊泡（EV）和其他纳米级别的大分子组件（统称为细胞外囊泡和颗粒或EVPS）的系统，准确和可重复的研究是由于缺乏可靠和可靠的工具，无法正确地测量这些smbsicicron和Nananscale材料。 CCR的使命是通过解决癌症研究和患者护理中的重要，具有挑战性和被忽视的问题来改善所有癌症患者的生活。 The Translational Nanobiology Section's particular expertise, perspective, collaborations, and vision within CCR is building bridges to span the existing gaps between basic biophysical and metrological first principles, advanced molecular multi-omics strategies, and clinical translational investigation in order to develop systematic, robust, and accurate ways to study EVPs tumor-, immune-, and stromal-/vascular- EVP compositions as they relate to tumor癌症患者的进展和治疗反应。尽管我的实验室的具体重点最直接与癌症和与癌症相关的免疫生物学有关，但我们打算成为生物医学研究界的一般资产。因此，我的部分致力于分享我们的一般研究用途的工具，以便它们也可以加速其他疾病的研究。 我计划的最终目标是利用EVP中的信息内容以系统的方式询问生物系统，即通过对EVP的特定子集的识别和表征来“读取”这些子集代表的隔间的状态。 转化纳米生物学实验室中项目1和2的目的是开发和证明使用新工具供该领域使用，这将使我们能够以我们希望我们能够进行血液测试的方式来监视肿瘤，免疫和血管/基质系统，以使我们能够在这些系统中进行相关的变化，以便在这些系统中检测到更广泛的系统，并希望能够以此为基础，并且希望能够以此为基础。未来的自适应治疗策略。项目1专注于跨越可用工具和知识的差距，以准确表征液体活检组件，EVP及其货物，用于项目2。